Literature DB >> 26312690

Primary cutaneous follicle center lymphoma simulating basal-cell carcinoma on the nasal ala.

Mariana Isis Wanczinsnki1, Clóvis Antonio Lopes Pinto1, Flávia Trevisan2, Paulo Rowilson Cunha1, Luz Marina Hannah Grohs1.   

Abstract

Primary cutaneous B-cell lymphomas (PCBCLs) constitute 25% of all primary cutaneous lymphomas. They present in the skin with no evidence of systemic or extracutaneous disease at the time of diagnosis, after adequate staging. Primary cutaneous B-cell lymphomas differ significantly from their nodal counterparts in relation to both clinical behavior and prognosis. The distinction between primary and secondary B-cell lymphomas is essential for defining prognosis/course of action. Such distinction is also very difficult to make, since primary and secondary B-cell lymphomas are clinically and histologically indistinguishable. We report the case of a patient with primary cutaneous follicle center lymphoma who underwent surgical excision.

Entities:  

Mesh:

Year:  2015        PMID: 26312690      PMCID: PMC4540524          DOI: 10.1590/abd1806-4841.20153768

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  2 in total

Review 1.  Primary cutaneous B-cell lymphomas: part II. Therapy and future directions.

Authors:  Andrea Luísa Suárez; Christiane Querfeld; Steven Horwitz; Melissa Pulitzer; Alison Moskowitz; Patricia L Myskowski
Journal:  J Am Acad Dermatol       Date:  2013-09       Impact factor: 11.527

Review 2.  Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification.

Authors:  Andrea Luísa Suárez; Melissa Pulitzer; Steven Horwitz; Alison Moskowitz; Christiane Querfeld; Patricia L Myskowski
Journal:  J Am Acad Dermatol       Date:  2013-09       Impact factor: 11.527

  2 in total
  1 in total

1.  Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report.

Authors:  Uwe Wollina; Dana Langner; Gesina Hansel; Gunter Haroske
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.